In fact, in cutaneous melanomas consistent improvements in disease outcome have been achieved in recent years using BRAF/MEK inhibitors and various immunotherapeutic agents, yet these approaches have failed in uveal melanomas [146]. This evidence concerns the gene BRAF and uveal melanoma.